ACVRL1 and hereditary hemorrhagic telangiectasia: The majority of the clinically diagnosed HHT patients have a mutation in the coding regions of the Endoglin (ENG) gene or activin A receptor type II-like 1 (ACVRL1) gene [9-15], leading to HHT1 or HHT2, respectively.